2024 July-雅法全球生物医药交易月报 YAFO Global Biopharma Transactions Report

学术   2024-08-02 08:01   菲律宾  

1. Executive Summary of the Month

2024年7月,全球医药市场共签署了60项资产授权和合作协议。其中,中国医药市场达成22项交易,包括12项出海交易、8项国内交易和2项引进交易。

本月中国市场最值得关注的出海交易是康诺亚向Belenos Biosciences授权两款临床前双抗资产CM512和CM536,首付款1500万美元,总价值1.85亿美元。最值得关注的国内交易是合一生技就其已获批药物ON101与华润双鹤达成的的授权交易,首付款3400万美元。

国际市场上,7月份共签署了38项资产授权和合作协议。最大的一笔交易是GSK与CureVac之间就后者的多项疫苗资产达成的合作,首付款4.33亿美元,总金额15.68亿美元。

In July, a total of 60 licensing and cooperation deals were signed globally. Within the China Biotech Industry, 22 deals were signed, including 12 out-licensing deals, 2 in-licensing deals, and 8 domestic deals.

The standout out-licensing deal of the month was between Keymed Biosciences and Belenos Biosciences for the pre-clinical assets CM512 and CM536, totaling $185 million with an upfront payment of $15 million. The highlight domestic deal was the licensing agreement between Oneness Biotech and Double-crane Pharmaceutical for the approved asset ON101, featuring an upfront payment of $34 million.

Globally, 38 licensing and cooperation deals were finalized. The most significant was the agreement between CureVac and GSK for multiple vaccine assets, totaling $1,568 million with an upfront payment of $433 million.

2. Licensing Deals



2a. Out-Licensing Deals




2b. In-Licensing Deals





2c. Domestic Licensing Deals











3. 2019-2023 China Innovative Drug Licensing Transactions



关于雅法资本(YAFO Capital)

雅法资本成立于2013年,作为新型投资和投行咨询机构,致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购,雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络,在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队,覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历,为客户交易提供强力支持。雅法总部位于上海,在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。

About YAFO Capital

Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions.  For more information, please visit www.yafocapital.com


药通中国近期活动



Event Name

2024-09  药通中国秋季路演,线上&云南
2024-09 ACCESS CHINA Autumn Roadshow, Virtual & Yunnan
2025-01 药通中国论坛@JPM,线上&旧金山
2025-01 ACCESS CHINA @ JPM Week, Virtual & San Francisco

雅法全球生命科学
雅法生命科学是雅法资本旗下专注医疗健康领域的投行部门。雅法全球生命科学将与您定期分享优质的海外医疗项目及最新的全球医疗行业资讯与行业分析。
 最新文章